Industry parts of Sun Pharmaceutical about 5 percent in early trading on Friday, May 23. This progress was prompted by investors in quarterly balanced sheets. The stock has fallen in an intraday under Rs 1,636.60 of the NSE, which is 4.77 percent of the past close to the end. Then, with a baby balanced sheet released in the post market, stock has been consumed.
Brokerage Radar
Sentiments sentiments remain post-roundons that most firms firms slap their targeted prices while positive ratings for stock.
Citi Its target rises in stock at Rs 2,210 from Rs 2,080, which deals positive views of future detection in the future specific view such as headwyck and leqselvi.
Jefferies Also maintained a “purchase,” but adjusts the target down Rs 2,000 from Rs 2,265.
Goldman Sachs A “sell” still remains and dropped their target at Rs 1,475.
Nomura stood “neutral”, but changed their target of Rs 1,970 quotes growing overheads that can negatively affect margins.
HSBC and JP Morgan They are also adjusted to their targets downward but maintain ‘buy’ and ‘overweight’.
